Osteoarthritis Market

• Osteoarthritis market size in the United States is expected to increase with a CAGR of 4.4% during the study period (2019–2032).
• Currently, the drugs used for the treatment of Osteoarthritis include NSAIDs, Opioids, Intra Articular Corticosteroids, Intra Articular-Hyaluronic acid and others.
• Leading Osteoarthritis companies working in the market are Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis, Kolon Tissuegene, Paradigm Biopharma, Novo Nordisk, Amzell, Nature Cell, Tissuetech, Techfields Pharma, Sorrento Therapeutics, Merck Kgaa, trialspark, Akl Research And Development, Medipost, Medivir, and others.

Request for Sample Report @ Osteoarthritis Market

DelveInsight's "Osteoarthritis Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Osteoarthritis , historical and forecasted epidemiology as well as the Osteoarthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Osteoarthritis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Osteoarthritis market size from 2019 to 2032. The report also covers current Osteoarthritis treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Osteoarthritis Disease Understanding and Treatment Algorithm

Osteoarthritis is the most common form of arthritis; it is a chronic degenerative joint disease that affects mostly middle-aged and older adults. Osteoarthritis causes the breakdown of joint cartilage. It can occur in any joint but most often affects the hands, knees, hips, or spine. Osteoarthritis can be divided into two types, primary and secondary. Osteoarthritis is broken down into five stages, as it can take many years to progress fully, it includes Stage 0, Stage 1: Minor, Stage 2: Mild, Stage 3: Moderate, and Stage 4: Severe.

Osteoarthritis Diagnosis

There is currently no standard lab test to verify the presence of Osteoarthritis Instead of a single lab test, physicians commonly use various diagnostic tools to determine if a patient has Osteoarthritis or another medical condition. However the diagnosis includes blood tests such as CBC, ESR, rheumatoid factor, and ANA are usually normal in Osteoarthritis X-rays of the affected joint can show findings consistent with Osteoarthritis and Ultrasound can also identify synovial inflammation, effusion, and osteophytes related to Osteoarthritis

Osteoarthritis Treatment

Osteoarthritis is a progressive and degenerative condition, with unlikely regression and restoration of damaged structures. Thus, current management modalities are targeted towards symptom control unless the degree of severity dictates the necessity of surgical intervention with joint replacement. The Current treatment of Osteoarthritis includes Nonsteroidal anti-inflammatory drugs (NSAIDS), Arcoxia (Etoricoxib), Opioids, Currently DUROLANE, GELSYN-3, CINGAL, JOYCLU and others HA formulations are available in market for the treatment of knee Osteoarthritis

Osteoarthritis Epidemiology

The Osteoarthritis epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Cases of Osteoarthritis Joint site-specific Prevalence of Osteoarthritis Gender-specific Prevalence of Osteoarthritis Age-specific Prevalence of Osteoarthritis Severity-specific Prevalence of Osteoarthritis in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the Osteoarthritis epidemiology in the 7MM

Country Wise- Osteoarthritis Epidemiology

The epidemiology segment also provides the Osteoarthritis epidemiology data and findings across in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

• The total number of diagnosed cases in the US rise from 2019-2032. In 2021, approximately 38 million cases of Osteoarthritis in the US. As per the analysis, a higher percentage of mild cases of Osteoarthritis was observed in the US, followed by moderate Osteoarthritis in 2021.
• In EU4 and the UK, in 2021, the highest proportion of age-specific cases were observed in 70 years and above, followed by age group of 60-69 years and 50-59 years.
• As per the analysis the highest percentage of gender-specific distribution of Osteoarthritis was observed among female population than the male population in 2021. About 24 million cases of Osteoarthritis in the US contributed by female population.
• As per the analysis, the highest percentage of Joint site-specific prevalence of Osteoarthritis in the US was observed in patients with knee Osteoarthritis followed by patients with Osteoarthritis of multiple joints and others. About 17 million cases were reported in knee Osteoarthritis patients, followed by approximately 11 million cases recorded in patients with Osteoarthritis of multiple joints and others.

Osteoarthritis Drug Chapters

The drug chapter segment of the Osteoarthritis report encloses the detailed analysis of Osteoarthritis mid and late stage pipeline drugs. It also helps to understand the Osteoarthritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Marketed Osteoarthritis drugs

ZILRETTA: Flexion Therapeutics/Pacira BioSciences

ZILRETTA is the first and only extended-release, intra-articular therapy for patients confronting Osteoarthritis knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide commonly administered, immediate-release corticosteroid – with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase III trial, on which the approval of Zilretta was based, showed that Zilretta significantly reduced Osteoarthritis knee pain for 12 weeks, with some people experiencing pain relief through Week 16. In October 2017, Flexion Therapeutics announced the US FDA approval of Zilretta, the first and only extended-release, intra-articular injection for knee Osteoarthritis In November 2022, company announced that launch of Phase III study in shoulder Osteoarthritis in 2023 and anticipating completion of study by 1H 2024.

CINGAL: Anika Therapeutics

CINGAL is the first and only commercially available combination viscosupplement and is currently being used successfully by physicians to provide rapid and long-lasting relief from pain and discomfort caused by Osteoarthritis for patients in a growing number of countries. CINGAL is a patented formulation composed of the company’s proprietary crosslinked sodium hyaluronate and triamcinolone hexacetonide. CINGAL is Anika’s third-generation viscosupplement to treat pain associated with knee Osteoarthritis following its other products, Orthovisc and Monovisc. In June 2016, Anika Therapeutics announced the commercial launch of CINGAL in the European Union. In November 2022, company announced positive Phase III data of CINGAL 19-01 study, as per the company statement it plans meeting with FDA to discuss next steps for the US regulatory approval. Moreover the company is actively assessing options to advance CINGAL, including potential commercial partnerships in the US and select Asian markets.

TRIVISC: OrthogenRx / Avanos Medical

TRIVISC is from a class of products known as hyaluronic acid, sodium hyaluronate, or hyaluronan (HA), also referred to as viscosupplementation therapy. It is used in a nonsurgical procedure that helps supplement the viscous properties of the fluid in the knee joint. In November 2017, the company announced that the US FDA had approved TRIVISC for the treatment of knee Osteoarthritis in patients who failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.

VISCO-3: Zimmer Biomet/Seikagaku Corporation

VISCO-3 is a solution made of highly purified sodium hyaluronate. Hyaluronan is a natural chemical found in the body and is found in particularly high amounts in joint tissues and in the fluid (synovial fluid) that fills the joints. In December 2015, Seikagaku Corporation (Tokyo) announced that the US FDA had approved VISCO-3 for the treatment of knee Osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

Note: Detailed Current therapies assessment will be provided in the full report of OA

Emerging Osteoarthritis Drugs

LNA043: Novartis

LNA043 is an ANGPTL3 (angiopoietin-like 3) agonist that targets damaged cartilage and modulates several pathways in cartilage regeneration. The drug is being developed as a potential first-in-class disease-modifying treatment for Osteoarthritis LNA043 is among several early investigational programs in Novartis’s portfolio that target cartilage damage and inflammation in Osteoarthritis In 2021, the US FDA granted Fast Track Designation (FTD) to LNA043 for knee Osteoarthritis treatment. A Phase IIb study (ONWARDS) in patients with knee Osteoarthritis is ongoing and the company anticipated the data readout for the Phase IIb (ONWARDS) trial by 2024. Additionally, the expected NDA submission for this trial is by 2026 and beyond. Apart from that, the company also anticipated presenting the data readout for another Phase II trial (NCT03275064) of LNA043 in patients with cartilage lesions of the knee (Part A) and knee Osteoarthritis (Part B) by 2022.

ReNu (Amniotic Suspension Allograft): Organogenesis

ReNu (Replace with NuTech Medical) is a cryopreserved, amniotic suspension allograft (ASA) to manage symptomatic knee Osteoarthritis It consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular matrix components. In January 2021, ReNu received the US FDA Regenerative Medicine Advanced Therapy (RMAT) designation for knee Osteoarthritis

JointStem: Naturecell

JointStem is the world’s first stem cell therapy for patients with severe knee Osteoarthritis It uses autologous adipose tissue-derived mesenchymal stem cells (AdMSC) that improve knee joint function and reduces pain; it also regenerates and improves knee cartilage. Unlike other existing similar drugs for degenerative arthritis, JointStem does not require repetitive injections periodically but requires only one injection of one dose. It is an innovative therapy without surgery. JointStem was approved for regenerative medical treatment for degenerative arthritis by Japan Health and Welfare Ministry in 2015 and is currently being treated at a local hospital in Japan.

CNTX-4975: Centrexion Therapeutics

Centrexion Therapeutics’ lead product candidate, CNTX-4975, is being evaluated for the treatment of moderate to severe pain of knee Osteoarthritis CNTX-4975 is an ultra-pure, synthetic form of trans-capsaicin injected directly into the pain site. In January 2018, the US FDA granted FTD to CNTX-4975 for treating the pain associated with knee Osteoarthritis Additionally, three Phase III clinical trials, namely VICTORY-1, VICTORY-2, and VICTORY-3 studies, are in progress for CNTX-4975 examining capsaicin and its potential to provide extended relief from knee Osteoarthritis

Note: Detailed emerging therapies assessment will be provided in the final report.

Osteoarthritis Market Outlook

Osteoarthritis (OA), also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage; it is most common in the elderly. Several pharmacologic treatments are available to manage knee Osteoarthritis-related pain and improve its functionality.

Common pharmacologic interventions to help alleviate knee Osteoarthritis symptoms include nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, intra-articular hyaluronic acid, and opioids. The US FDA-approved sodium hyaluronate includes SUPARTZ (Smith & Nephew) – approved on January 24, 2001; ORTHOVISC (Anika Therapeutics) – approved on February 4, 2004; EUFLEXXA (Ferring Pharmaceuticals) – approved in 2005; and GEL-ONE Cross-linked Hyaluronate (Seikagaku Corporation) – approved in 2011. In October 2017, Flexion Therapeutics announced the US FDA approval of ZILRETTA for knee Osteoarthritis The pivotal Phase III trial, on which the approval of Zilretta was based, showed that ZILRETTA significantly reduced Osteoarthritis knee pain for 12 weeks, with some people experiencing pain relief through Week 16.

The current developmental pipeline for knee Osteoarthritis is robust; several companies have initiated clinical trials investigating new treatment options or studying how to use existing treatment options better. The dynamics of the Osteoarthritis market are also anticipated to change in the coming years, owing to the rise in healthcare spending globally.

Key Findings

This section includes a glimpse of the Osteoarthritis the 7MM

• The United States accounts for the largest Osteoarthritis market size in comparison to EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
• Among EU4 countries, Germany had the highest Osteoarthritis market size in 2021, while Italy had the smallest Osteoarthritis market size in 2021.
• Currently, the drugs used for the treatment of Osteoarthritis include NSAIDs, Opioids, Intra Articular Corticosteroids, Intra Articular-Hyaluronic acid and others.
• The upcoming therapies of Osteoarthritis are expected to combat the current unmet needs faced by the patients with Osteoarthritis

The United States: Osteoarthritis Market Outlook

The total Osteoarthritis market size in the United States is expected to increase with a CAGR of 4.4% during the study period (2019–2032).

EU4 and the UK: Osteoarthritis Market Outlook

The total Osteoarthritis market size in EU4 and the UK is expected to increase with a CAGR of 2.7% during the study period (2019–2032).

Analyst Commentary

• The current developmental pipeline for knee Osteoarthritis is robust; several companies have initiated clinical trials investigating new treatment options or studying how to use existing treatment options better. The dynamics of the knee Osteoarthritis market are also anticipated to change in the coming years, owing to the rise in healthcare spending globally.
• Lucrative opportunities in nations where single-injection joint function-enhancing drugs are unavailable. The growth of the Osteoarthritis market is driven by an increase in the geriatric population and obesity
• Many key players are developing cell therapies for Osteoarthritis in various stages of development. If approved, these therapies may provide better treatment options as they can slow disease progression and possibly cure the disease

Osteoarthritis Drugs Uptake

This section focusses on the rate of uptake of the potential Osteoarthritis drugs expected to get launched in the market during the study period 2019-2032. The analysis covers Osteoarthritis market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Zilosul (PPS), is a Non-nucleoside reverse transcriptase inhibitors. Currently, the drug is in the Phase III stage of clinical development for Osteoarthritis. In April 2022, the company announced that FDA has granted Fast Track Designation (FTD) to pentosan polysulfate sodium (PPS; ZILOSUL) for the treatment of Osteoarthritis. The drug is expected to launch in the US in 2025. As per our analysis, Zilosul drug uptake in the US is expected to be medium and probability adjusted peak share is 0.4%.

Osteoarthritis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II. It also analyzes Osteoarthritis companies involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Osteoarthritis emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders are Chief Executive Officer, MD, chief medical officer of Centrexion, MD, University of Texas at Houston and Director of Chronic Pain at Lotus Clinical Research, An official from PMG Pharmaceuticals and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Osteoarthritis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Osteoarthritis market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Osteoarthritis Report

• The report covers the descriptive overview of Osteoarthritis, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Osteoarthritis epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Osteoarthritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Osteoarthritis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Osteoarthritis market.

Osteoarthritis Report Highlights

• Many key players are developing cell therapies for Osteoarthritis in various stages of development. If approved, these therapies may provide better treatment options as they can slow disease progression and possibly cure the disease
• Companies are investing heavily in developing disease-modifying therapies for the treatment of Osteoarthritis which will fulfill a major unmet need
• The report also encompasses other major segments, i.e Total Diagnosed Cases of Osteoarthritis Joint site-specific Prevalence of Osteoarthritis Gender-specific Prevalence of Osteoarthritis Age-specific Prevalence of Osteoarthritis Severity-specific Prevalence of OA
• Expected Launch of potential therapies LNA043 (Novartis), ReNu (Organogenesis), AMZ001 (Amzell), JointStem (Naturecell), and others might change the landscape in treatment of Osteoarthritis

Osteoarthritis Market Report Insights

• Osteoarthritis Patient Population
• Osteoarthritis Therapeutic Approaches
• Osteoarthritis Pipeline Analysis
• Osteoarthritis Market Size and Trends
• Osteoarthritis Market Opportunities
• Impact of upcoming Osteoarthritis Therapies

Osteoarthritis Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Osteoarthritis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Osteoarthritis Market
• Osteoarthritis Drugs Uptake

Osteoarthritis Market Assessment

• Current Treatment Practices
• Osteoarthritis Unmet Needs
• Osteoarthritis Pipeline Product Profiles
• Osteoarthritis Market Attractiveness
• Osteoarthritis SWOT Analysis
• Attribute Analysis

Key Questions

Osteoarthritis Market Insights:

• What was the Osteoarthritis market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Osteoarthritis total market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Osteoarthritis market size during the study period (2019–2032)?
• At what CAGR, the Osteoarthritis market is expected to grow at the 7MM level during the study period (2019–2032)?
• What would be the Osteoarthritis market outlook across the 7MM during the study period (2019–2032)?
• What would be the Osteoarthritis market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Osteoarthritis Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Osteoarthritis ?
• What is the historical Osteoarthritis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Osteoarthritis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Osteoarthritis ?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Osteoarthritis during the study period (2019–2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Osteoarthritis ? What are the current treatment guidelines for the treatment of Osteoarthritis in the US and Europe?
• What are the Osteoarthritis marketed drugs and their MOsteoarthritis regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Osteoarthritis ?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Osteoarthritis ?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the ongoing Osteoarthritis clinical studies and their status?
• What are the key designations that have been granted for the emerging therapies for Osteoarthritis ?
• What are the 7MM historical and forecasted market of Osteoarthritis ?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Osteoarthritis .
• To understand the future market competition in the Osteoarthritis market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Osteoarthritis in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Osteoarthritis market.
• To understand the future market competition in the Osteoarthritis market.